187 results about "Reduced dose" patented technology

A test strip with a sample receiving chamber having a novel flared portion that terminates in a sample receiving opening. The flared portion provides a reservoir from which sample fluid can be drawn into the capillary or sample receiving chamber. The wider opening provided by the present invention is easier to “target” with a sample fluid. In preferred embodiments, the hydrophilic reagent layer extends to the dosing end or side of the test strip and further promotes wicking of the sample into the sample receiving chamber and thus reduces dose hesitation. In other preferred embodiments, a tapered dosing end is provided on the test strip in combination with the flared portion, and this combination create a test strip that will draw sample fluid into the sample receiving chamber regardless of where along the dosing edge of the test strip the fluid sample makes contact.

A pharmaceutical paste composition comprising an active ingredient such as an addictive substance, a controlled release agent, and a pharmaceutically suitable aqueous or non-aqueous carrier. The composition may comprise one or more of a clay, or an oily, waxy, or fatty substance. The composition may be filled into a capsule or other dispensing device. The composition may reduce dose dumping of an active ingredient. Methods of making and using the composition are also described.

The invention provides an automatic control system for variable pesticide spraying of a rice unmanned aerial vehicle based on image processing. The automatic control system comprises a field information acquiring module, an information processing module, an information management decision-making module and an unmanned aerial vehicle variable spraying control module. The automatic control system and the automatic control method for variable pesticide spraying of the rice unmanned aerial vehicle based on image processing can set different dose prescription values according to disaster severity degrees of different plots so as to achieve better pest control effect, reduces agricultural cost and reduces dose. By combining the unmanned aerial vehicle pesticide spraying with a variable pesticide spraying technology, the pesticides are sprayed according to the practical damage condition changes of crops, so that the operation efficiency is improved, the dose of pesticides is reduced, the environmental pollution is relieved, the crop growth is facilitated, and the visual operation is realized by virtue of a real-time monitoring and display system.

Method and system for computed tomography. Data is collected by irradiating a subject with x-rays. The data is interpolated and then weighted based upon the data collection time. The interpolated and weighted data is then used to reconstruct the image using fan beam reconstruction. The weighting function may by shifted in time. Signals may be obtained from the subject and used to control exposure, reduce the dose and provide automatic volumetric cardiac reconstruction. The method and system can increase the temporal and spatial resolution, and reconstruct images at different timing.

A method and apparatus is disclosed to acquire scout scan data of a subject and analyzed to determine a peak-to-peak modulation amplitude of a normalized waveform indicative of subject size and shape. The scout scan data provides a representation of patient size and shape that is associated with an ideal tube current modulation waveform or profile. The ideal tube current modulation profile may then be sampled or approximated at various points to determine a tube current modulation profile for implementation to acquire CT data with reduced dose but without sacrificing image quality.

This invention relates to the use of thick target materials 50 microns and thicker for an x-ray transmission tube; to possible target material compositions including various elements and their alloys, eutectic alloys, compounds, or intermetallic compounds; and applications for utilizing such thick target transmission x-ray tubes. The target comprises at lease one portion of the target with a thickness of 50 microns or greater. The target can be optionally attached to a substrate end-window essentially transparent to x-rays or be thick enough so that no such substrate is required. Applications include producing a high percentage of monochromatic line mission x-rays of said thick target for use in reduced dose medical imaging and other non-destructive testing applications.

This invention relates to the use of thick target materials 50 microns and thicker for an x-ray transmission tube; to possible target material compositions including various elements and their alloys, eutectic alloys, compounds, or intermetallic compounds; and applications for utilizing such thick target transmission x-ray tubes. The target comprises at lease one portion of the target with a thickness of 50 microns or greater. The target can be optionally attached to a substrate end-window essentially transparent to x-rays or be thick enough so that no such substrate is required. Applications include producing a high percentage of monochromatic line mission x-rays of said thick target for use in reduced dose medical imaging and other non-destructive testing applications.

A radiographic X-ray apparatus is equipped with multiple devices for the acquisition of anatomical data, in particular cameras. These devices are used to facilitate and automate the imaging process, providing: before exposure the automated identification of the specific anatomical features of the patient and the optimized presetting of the exposure technique factors and projection geometry, tailored on the actual anatomy of the patient; during exposure the optimized X-ray dose modulation, either automatically or selected by the operator, in order to correctly expose the various regions of interest, and accordingly impart reduced dose to other body parts, according to the actual anatomy of the patient and imaging requirements; after exposure the possibility to complement the radiographic image with additional information about the internal and external anatomy, providing valuable tools for the medical analysis and diagnosis.

This method provides a method for reducing HIV-1 viral load in an HIV-1-infected human subject which comprises administering to the subject at a predefined interval effective HIV-1 viral load-reducing doses of (a) a humanized antibody designated PRO 140, or of (b) an anti-CCR5 receptor monoclonal antibody. This invention also provides a method for inhibiting in a human subject the onset or progression of an HIV-1-associated disorder, the inhibition of which is effected by inhibiting fusion of HIV-1 to CCR5+CD4+ target cells in the subject. This invention also provides a method for treating a subject infected with HIV-1 comprising administering to the subject (a) a monoclonal antibody which (i) binds to a CCR5 receptor on the surface of the subject's CD4+ cells and (ii) inhibits fusion of HIV-1 to the subject's CCR5+CD4+ cells, and (b) a non-antibody CCR5 receptor antagonist, in amounts effective to treat the subject.

A chemically modified human Growth Hormone (rhGH) prepared by attaching a transient linker which comprises a polyethylene glycol. The chemically modified protein may have a much longer lasting rhGH activity than that of the unmodified rhGH, enabling reduced dose and scheduling opportunities and the modified rhGH may not cause lipoatrophy. Also includes methods of use for the treatment and / or prevention of diseases or disorders in which use of growth hormone is beneficial.

Systems and methods for rotating shield brachytherapy. In an aspect, some of the systems and methods can be used to facilitate shield selection for use in rotating shield brachytherapy. In an aspect, the invention is a shielded needle or catheter system with a rotational controller for delivering radioisotope-based interstitial rotating shield brachytherapy (I-RSBT), In an aspect, I-RSBT needles can deliver dose distributions that can be non-radially symmetric about each needle, enabling reduced doses to sensitive normal tissues. Further provided are methods and systems for selecting an emission angle for use in S-RSBT and for sequencing the rotating shields. Further provided are methods and system for the multiple application of M-RSBT in a single setting.

The present invention utilizes ultramicropulverization and dripping pill preparation production process to make cucurbitacin dripping pills, and can attain the goal of raising disintegration and dissolution speed, quickly obtaining therapeutic effect, raising stability of medicine, reducing dose of auxiliary material, reducing production cost and convenient administration. Said pill not only can be sucked, but also can be swallowed.

A stable packaged bicarbonate solution for use in dialysis treatment and for treating anemia, iron deficiency, or reducing the required dose of recombinant erythropoietin to treat anemia includes a bicarbonate solution into which ferric pyrophosphate is dissolved. The amount of ferric pyrophosphate dissolved in the bicarbonate solution is sufficient to provide a therapeutic effect for the treatment of anemia, iron deficiency or to reduce dose of recombinant erythropoietin needed to treat anemia when the bicarbonate solution is combined with other dialysis components to form a dialysate used for dialyzing a patient. The ferric pyrophosphate is stabilized in the bicarbonate solution by holding the solution in a polyolefin container or container liner, such as a high density polyethylene container or liner.

A new formulation of dehydrated lipid vesicles employs a vesicle preserver and permits the control of release and delivery of active pharmaceutical ingredients into the respiratory system for treatment in particular of asthma. The typical formulation provides controlled release of the active pharmaceutical ingredient from 0% to 100% from 0 to 72 hours after inhalation, changes the systemic administration to topical administration, allows prolonged therapeutic period for one administration, increased stability, with reduced dose, reduced systemic side effects, reduced toxicity.

A system and method for reconstructing an image acquired by delivering an irradiating dose of radiation to a subject includes acquiring imaging data using a dose of irradiating radiation and selecting at least one of a plurality of mechanisms for reducing the dose that could be delivered to the subject to acquire additional imaging data. Noise is inserted into the imaging data to simulate the at least one of the plurality of mechanisms for reducing the dose that could be applied to acquire the additional imaging data to thereby generate simulated imaging data at a reduced dose of irradiating radiation. A simulated reduced dose image is reconstructed from the simulated imaging data. A method is provided for utilizing a non-local means filter adapted using a map of local noise to produce denoised medical imaging data reflecting reduced local nose levels from those in originally-acquired medical imaging data.

The standard dose of polio vaccines contains 40 D-antigen units of inactivated poliovirus type 1 (Mahoney), 8 D-antigen units of inactivated poliovirus type 2 (MEF-1), and 32 D-antigens units of inactivated poliovirus type 3 (Saukett). The present invention teaches that reduced doses of inactivated poliovirus can maintain adequate or improved level of protection against polio.

Described herein are compositions and methods for intravenous administration of acetaminophen at a single dose level of less than about 1000 mg for the treatment or prevention of pain (e.g., postoperative pain) and / or fever.

The present disclosure provides for methods of treating a patient with a CYP3A4 substrate drug contraindicated for concomitant administration with a strong CYP3A4 inhibitor, wherein the patient is treated with multiple doses of posaconazole, stops posaconazole treatment, and then is treated with the CYP3A4 substrate drug. In some embodiments, treatment with the CYP3A4 substrate drug is delayed for about 2-21 after stopping posaconazole. In some embodiments, the patient is treated with or prescribed a reduced dose of the CYP3A4 substrate drug for about 2-21 after stopping posaconazole.

A beam shaping assembly for neutron capture therapy includes a beam inlet, a target having nuclear reaction with an incident proton beam from the beam inlet to produce neutrons forming a neutron beam defining a main axis, a moderator adjoining to the target, a reflector surrounding the moderator, a thermal neutron absorber adjoining to the moderator, a radiation shield arranged inside the beam shaping assembly and a beam outlet. The neutrons are moderated to epithermal neutron energies. An outer surface of the moderator includes at least a first tapered section. The reflector leads the neutrons deviated from the main axis back. The thermal neutron absorber is used for absorbing thermal neutrons so as to avoid overdosing in superficial normal tissue during therapy. The radiation shield is used for shielding leaking neutrons and photons so as to reduce dose of the normal tissue not exposed to irradiation.

A system and method is provided for imaging a region of interest (“ROI”) including a breast having received a reduced dose of radionuclide using an imaging system including at least two gamma detectors. The acquired imaging data is analyzed respect to an energy characteristic and divided into subsets of data based on the analysis. A plurality of images is generated using the subsets of data, wherein the plurality of images include a primary image corresponding to subsets of data having energy including the energy characteristic and multiple secondary images corresponding to subsets of data having energy not including the energy characteristic. Each of the plurality of images is processed using energy information associated with each of the plurality of images and the processed plurality of images is combined to form a composite image of the ROI.

The present disclosure provides for methods of treating a patient with a CYP3A4 substrate drug, wherein the patient is treated with posaconazole. In some embodiments, the patient stops posaconazole treatment, waits for at least 2 days, and then is treated with the CYP3A4 substrate drug as soon as it is safe to do so. In some embodiments, treatment with the CYP3A4 substrate drug is delayed for about 2-42 days after stopping posaconazole. In some embodiments, the patient is treated with a reduced dose of the CYP3A4 substrate drug for about 2-42 days.

The invention relates to a cyclosporine A micelle eye drop and a preparing method thereof. The cyclosporine A micelle eye drop comprises cyclosporine A used as a main drug, aseptic and isoosmotic adjusting agents, and is characterized by further comprising a copolymer of polythene caprolactam, polyvinyl acetate and polyethylene glycol used as drug auxiliary materials. The preparing method includes: preparing a cyclosporine A micelle through a solvent rotary evaporation film forming method; obtaining cyclosporine A micelle powder after filtering, freezing and drying the cyclosporine A micelle; and dispersing and dissolving the powder into a buffer solution to obtain the cyclosporine A micelle eye drop. According to the cyclosporine A micelle eye drop, the cyclosporine A has good solubility in a water solution, the micelle is small in particle diameter and uniform in distribution range and drug stability is good. The cyclosporine A micelle eye drop not only reduces drug irritation, but also improves drug absorption of a cornea, reduces drug concentration, prolongs drug action time, reduces dosing frequency, improves patient compliance, and has good economical efficiency.

The invention is directed to novel pharmaceutical compositions comprising chemicals agents that are useful in the treatment and prevention of cystic fibrosis and the prevention of signs and symptoms of this disease. These pharmaceutical compositions are surprisingly successful in the treatment disorders related to cystic fibrosis including disorders of blood production. Many of these compositions of the invention are even more effective when administered to a patient in pulses. Pulse therapy is not a form of discontinuous administration of the same amount of a composition over time, but comprises administration of the same dose of the composition at a reduced frequency or administration of reduced doses.

The invention discloses a gynaecologic restorative pharmaceutic preparation and a preparation technology and a quality control method thereof, belonging to the field of traditional Chinese medicines. The preparation is prepared by adopting novel technology on the basis of the original gynaecologic restorative bolus and inducing an auxiliary material ultrafine grinding technology, thereby not only maintaining the compound grinding homogenization, but also maintaining active ingredients to the maximum, greatly enhancing the curative effect, enhancing the use ratio of medicinal materials and also reducing dose.

A radiographic X-ray apparatus is equipped with multiple devices for the acquisition of anatomical data, in particular cameras. These devices are used to facilitate and automate the imaging process, providing: before exposure the automated identification of the specific anatomical features of the patient and the optimized presetting of the exposure technique factors and projection geometry, tailored on the actual anatomy of the patient; during exposure the optimized X-ray dose modulation, either automatically or selected by the operator, in order to correctly expose the various regions of interest, and accordingly impart reduced dose to other body parts, according to the actual anatomy of the patient and imaging requirements; after exposure the possibility to complement the radiographic image with additional information about the internal and external anatomy, providing valuable tools for the medical analysis and diagnosis.

A method and apparatus is disclosed to acquire scout scan data of a subject and analyzed to determine a peak-to-peak modulation amplitude of a normalized waveform indicative of subject size and shape. The scout scan data provides a representation of patient size and shape that is associated with an ideal tube current modulation waveform or profile. The ideal tube current modulation profile may then be sampled or approximated at various points to determine a tube current modulation profile for implementation to acquire CT data with reduced dose but without sacrificing image quality.

Methods, systems, and apparatus for obtaining a sequence of x-ray images are disclosed. An object of interest in a first x-ray image is detected and an area of interest, based on a predicted motion of the object of interest, is determined. A second x-ray image of the area of interest is acquired using spatial x-ray modification to control an x-ray to pass through a portion of a patient corresponding to the area of interest.

Drug-polymer chemotherapeutics are provided having improved therapeutic efficacy and reduced dose-limiting toxicity. Methods are also provided for modulating the architecture, pharmacokinetics and biodistribution of drug-polymers and for reducing the dependence of transition temperature on concentration for drug-polymers.